U.S. markets closed

Novo Nordisk A/S (NVO)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
95.16-0.28 (-0.29%)
At close: 04:00PM EST
94.70 -0.46 (-0.48%)
After hours: 05:43PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close95.44
Bid94.66 x 900
Ask95.18 x 900
Day's Range93.99 - 95.87
52 Week Range66.59 - 117.35
Avg. Volume1,281,261
Market Cap218.444B
Beta (5Y Monthly)0.26
PE Ratio (TTM)31.26
EPS (TTM)3.04
Earnings DateN/A
Forward Dividend & Yield1.47 (1.54%)
Ex-Dividend DateAug 16, 2021
1y Target Est115.85
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-8% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for NVO

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Novo Nordisk A/S
    Analyst Report: Novo Nordisk A/SWith almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
    Fair Value
    Economic Moat
    19 days agoMorningstar
View more